From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension.
about
Molecular mechanisms of pulmonary arterial remodelingCombination therapy in pulmonary arterial hypertension: recent accomplishments and future challengesPulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies.Elevated microRNA-135a is associated with pulmonary arterial hypertension in experimental mouse model.Regulation of ca(2+) signaling in pulmonary hypertension.Signal transduction in the development of pulmonary arterial hypertensionNur77 suppresses pulmonary artery smooth muscle cell proliferation through inhibition of the STAT3/Pim-1/NFAT pathwayThe emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future.STAT3 signaling in pulmonary arterial hypertension.Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series).Novel Targets of Drug Treatment for Pulmonary Hypertension.MicroRNAs in Bladder Outlet Obstruction: Relationship to Growth and Matrix Remodelling.The first Keystone Symposia Conference on pulmonary vascular isease and right ventricular dysfunction: Current concepts and future therapies.MicroRNAs-control of essential genes: Implications for pulmonary vascular disease.Dysregulation of microRNA-214 and PTEN contributes to the pathogenesis of hypoxic pulmonary hypertension.Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words.Dual ETA/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension.
P2860
Q26991806-6F3F73FA-077A-49DE-8C83-78BC23C66ABEQ33788582-A6FE3084-8C2A-492D-84E9-54267E5B464BQ33810499-74BD9E93-38F1-47B4-B513-685FDBB9AF0EQ33829248-015BBF23-899F-46E0-8A2B-9B759F264BCDQ36628777-A62167B1-979C-4FFD-AAB3-5F5EDCDA0545Q37133785-4CA96C98-3EBC-4E5A-9A04-9DC3971EB13BQ37596153-4CA0ACF1-EC56-4B7B-8AE1-243A6B5BA480Q38077796-8FC08738-34C6-479E-A4A6-D44566595801Q38140894-B75B0688-BDB7-4FAB-B530-CFDAD255FD83Q38227557-31D18088-84B4-4211-B9CB-98904D21F07DQ38504399-1C03A9BC-5225-4249-803E-E92FD9516B9BQ38650105-C8C3651D-57A6-4E69-86C5-2C842D5283CBQ39353707-FA6C435C-5D54-4CA7-96E8-4C3C328DA79DQ39385085-5842B149-C481-43FB-8D15-00397F02B39EQ41034799-CD08885D-2AC4-4232-ABAE-B239F84D864FQ46682354-1ABC5C2B-3CF2-4A89-8FFD-7A2BD4D4D6B0Q49312062-8E73C601-3F9F-48CA-958E-F16A5243C949Q49882973-55CC71D0-CB00-44CA-94EE-735059AD4A8C
P2860
From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
From oncoproteins/tumor suppre ...... lmonary arterial hypertension.
@en
From oncoproteins/tumor suppre ...... lmonary arterial hypertension.
@nl
type
label
From oncoproteins/tumor suppre ...... lmonary arterial hypertension.
@en
From oncoproteins/tumor suppre ...... lmonary arterial hypertension.
@nl
prefLabel
From oncoproteins/tumor suppre ...... lmonary arterial hypertension.
@en
From oncoproteins/tumor suppre ...... lmonary arterial hypertension.
@nl
P2093
P2860
P1476
From oncoproteins/tumor suppre ...... lmonary arterial hypertension.
@en
P2093
Audrey Courboulin
Marjorie Barrier
Roxane Paulin
Sébastien Bonnet
P2860
P2888
P304
P356
10.1007/S00109-011-0788-5
P577
2011-07-15T00:00:00Z